Company
St Lucia, QLD
Every published round The University of Queensland took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies The University of Queensland has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
This is a stake in the fund itself, money that the fund's manager invests, not a stake in the fund manager.
| Fund | Manager | Sources |
|---|---|---|
| Uniseed | Uniseed | GBS Ventures, clinicalleader.com |
Companies The University of Queensland has backed that another company then bought. An exit for the holding, not a deal The University of Queensland did.
| Name | Role | Sources |
|---|---|---|
| Dr Aiden Beauglehole | Senior Scientific Officer | FaBA |
| Dr Bruce Wyse | GBS Ventures, clinicalleader.com | |
| Dr David Muller | Brandon BioCatalyst portfolio, Brandon Capital portfolio | |
| Dr Michael Smart | Chair of Hypersonic Propulsion (former) | @AuManufacturing |
| Prof Maree Smith | GBS Ventures (30 Jun 2015), clinicalleader.com, GBS Ventures (3 Aug 2006) | |
| Professor Esteban Marcellin | Professor | FaBA |
Stories naming The University of Queensland. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian medtech Ceretas hit a milestone in its CUREator+ program, unlocking the final instalment of a government-funded grant; the piece also recaps its A$8 million IPO and ASX listing earlier in 2026.
FaBA profiles Pollinate, a Brisbane startup founded by Adeep Mitra and Corey Berther that uses AI to automate food supply chain workflows, tracing its path from a university food challenge to Y Combinator backing.
A green-methanol developer announces a 1.4 million dollar federal CRC-P grant toward a 2.8 million dollar pilot plant with university and utility partners, plus a new lead chemist joining.
Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.
Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily
Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.
Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily
Queensland drug developer Lucia Bio added $2 million to its seed round from UniQuest Extension Fund and Uniseed-managed funds, bringing its overall raise to $3 million ahead of a planned Series A.
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
FaBA's accelerator program has handed a University of Queensland precision-fermentation dairy process to Sydney startup All G, which will scale it toward a milk supplement, with federal government support.
FaBA and UQ launch their largest research project, a $5.6m effort with oat company My PlantCo to develop new oat-based foods, with GRDC committing over $720,000 to the company's project.
UniQuest and Molecule to Medicine have formed Curlew Bio to develop anti-inflammatory drugs, backed by $1 million from UniQuest's Extension Fund; the article also recalls Novartis's 2015 purchase of Spinifex Pharmaceuticals.
Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia
FaBA introduces its newly appointed commercialisation director, who discusses his microbiome industry background and the accelerator's co-funded research projects for industry partners.
AuManufacturing roundup of brief industry news: Wide Open Agriculture banks a $7.5 million raise, Liontown adds a lithium offtake partner, Osteopore signs Zimmer Biomet for distribution, plus quantum, defence, rail and recycling items.
Hypersonix has appointed Arthur Sinodinos, a former Australian ambassador to the United States, as its board chair. Co-founder David Waterhouse becomes deputy chair. The company won its first US defence contract last year.
Roundup of Australian manufacturing briefs: Nova Eye Medical banks $8m, Ridley buys Oceania Meat Processors, Orica sells Deer Park land for $260m, plus appointments, research projects and CSIRO program deadlines.
Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.
Australian precision fermentation startup Nourish Ingredients secures government funding and grants, recalls its Series A, and outlines plans to launch its first animal-like fat in late 2024.
Also AgFunderNews
Queensland and Germany launch a joint bioeconomy research programme backed by $3 million, while the article recalls Vast Solar and the Solar Methanol Consortium winning HyGATE grant funding for a green methanol plant in Port Augusta.
Vaxxas, with Queensland Government backing, has opened its Brisbane global headquarters and vaccine patch manufacturing facility, supported by state and federal government funding.
Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.
Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.
Vaxxas has appointed 23-year Pfizer veteran Dr Rochelle Chaiken as chief medical officer; the announcement also recaps the vaccine-patch company's early backing by OneVentures, Brandon Capital and others.
Vaxxas has begun an Australian Phase I trial of its needle-free influenza vaccine patch. The article also recalls the company's founding equity financing led by OneVentures with Brandon Capital Partners and other co-investors.
FaBA appoints Dr Chris Downs, a veteran agri-food scientist and executive from CSIRO and Queensland government, as Director of the national food and beverage accelerator.
Vaxxas partners with CEPI, which will fund preclinical testing of its needle-free vaccine patch for mRNA vaccines, work that could remove cold-storage needs and widen global access to such vaccines.
Also Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing
Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.
Also OneVentures portfolio·Brandon Capital portfolio·@AuManufacturing·SmartCompany·Techboard·@AuManufacturing
Eight projects share 28.9 million dollars in Australian government grants under the National Soil Carbon Innovation Challenge, funding cheaper technologies for measuring soil organic carbon, with ministers Bowen and Watt announcing the recipients.
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch, built on a University of Texas at Austin candidate; the article also recalls the company's early financings led by OneVentures.
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.
Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·novartis.com·clinicalleader.com·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia
Spinifex Pharmaceuticals won a $1.67 million federal Commercial Ready grant to advance its neuropathic pain drug, after a $3.25 million syndicate raise the previous July; it was spun out of the University of Queensland.